Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitudinal assessment may provide data predicting efficacy. We sought to examine the impact of dNLR dynamics on ICI efficacy and understand its biological significance.aNSCLC patients receiving ICI at 17 EU/US centres...